Intranasal administration of adjuvant-combined vaccine protects monkeys from challenge with the highly pathogenic influenza A H5N1 virus

Journal of Medical Virology

Volumn 82, Issue 10, 2010, Pages 1754-1761

  Ichinohe, Takeshi ^a,b,d   Ainai, Akira ^a   Ami, Yasushi ^a   Nagata, Noriyo ^a   Iwata, Naoko ^a   Kawaguchi, Akira ^a,b   Suzaki, Yuriko ^a   Odagiri, Takato ^a   Tashiro, Masato ^a   Takahashi, Hidehiro ^a   Strayer, David R ^c   Carter, William A ^c   Chiba, Joe ^b   Tamura, Shin Ichi ^a   Sata, Tetsutaro ^a   Kurata, Takeshi ^a   Hasegawa, Hideki ^a  

^a NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^b TOKYO UNIVERSITY OF SCIENCE   (Japan)

^c HEMISPHERX BIOPHARMA INC   (United States)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adjuvant; Cynomolgus macaques; H5N1 influenza A virus; IgA; Intranasal vaccine

Indexed keywords

DOUBLE STRANDED RNA; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; INFLUENZA VACCINE;

ADJUVANT THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPERIMENTAL MONKEY; FEMALE; IMMUNIZATION; INFLUENZA A (H5N1); INFLUENZA VIRUS A H5N1; MALE; NONHUMAN;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; IMMUNIZATION, SECONDARY; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; MACACA FASCICULARIS; MALE; NEUTRALIZATION TESTS; ORTHOMYXOVIRIDAE INFECTIONS; RNA, DOUBLE-STRANDED; SALIVA; VACCINATION;

ANIMALIA; INFLUENZA A VIRUS; MACACA;

EID: 77956585400     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.21824     Document Type: Article

References (20)

1. Unknown. 2004. Mismatched double-stranded RNA: PolyI:polyC12U. Drugs Res Dev 5: 297-304.
2. Asahi Y, Yoshikawa T, Watanabe I, Iwasaki T, Hasegawa H, Sato Y, Shimada S, Nanno M, Matsuoka Y, Ohwaki M, Iwakura Y, Suzuki Y, Aizawa C, Sata T, Kurata T, Tamura S. 2002. Protection against influenza virus infection in polymeric Ig receptor knockout mice immunized intranasally with adjuvant-combined vaccines. J Immunol 168:2930-2938.
3. Asahi-Ozaki Y, Itamura S, Ichinohe T, Strong P, Tamura S, Takahashi H, Sawa H, Moriyama M, Tashiro M, Sata T, Kurata T, Hasegawa H. 2006. Intranasal administration of adjuvant-combined recombinant influenza virus HA vaccine protects mice from the lethal H5N1 virus infection. Microbes Infect 8:2706-2714.
4. Claas EC, Osterhaus AD, van Beek R, De Jong JC, Rimmelzwaan GF, Senne DA, Krauss S, Shortridge KF, Webster RG. 1998. Human influenza A H5N1 virus related to a highly pathogenic avian influenza virus. Lancet 351:472-477.
5. Gao P, Watanabe S, Ito T, Goto H, Wells K, McGregor M, Cooley AJ, Kawaoka Y. 1999. Biological heterogeneity, including systemic replication in mice, of H5N1 influenza A virus isolates from humans in Hong Kong. J Virol 73:3184-3189.
6. Hasegawa H, Ichinohe T, Tamura S, Kurata T. 2007. Development of a mucosal vaccine for influenza viruses: Preparation for a potential influenza pandemic. Expert Rev Vaccines 6:193-201.
7. Horimoto T, Fukuda N, Iwatsuki-Horimoto K, Guan Y, Lim W, Peiris M, Sugii S, Odagiri T, Tashiro M, Kawaoka Y. 2004. Antigenic differences between H5N1 human influenza viruses isolated in 1997 and 2003. J Vet Med Sci 66:303-305.
8. Ichinohe T, Watanabe I, Ito S, Fujii H, Moriyama M, Tamura S, Takahashi H, Sawa H, Chiba J, Kurata T, Sata T, Hasegawa H. 2005. Synthetic double-stranded RNA poly(I:C) combined with mucosal vaccine protects against influenza virus infection. J Virol 79:2910-2919.
9. Ichinohe T, Kawaguchi A, Tamura S, Takahashi H, Sawa H, Ninomiya A, Imai M, Itamura S, Odagiri T, Tashiro M, Chiba J, Sata T, Kurata T, Hasegawa H. 2007a. Intranasal immunization with H5N1 vaccine plus Poly I:Poly C12U, a Toll-like receptor agonist, protects mice against homologous and heterologous virus challenge. Microbes Infect 9:1333-1340.
10. Ichinohe T, Tamura S, Kawaguchi A, Ninomiya A, Imai M, Itamura S, Odagiri T, Tashiro M, Takahashi H, Sawa H, Mitchell WM, Strayer DR, Carter WA, Chiba J, Kurata T, Sata T, Hasegawa H. 2007b. Cross-protection against H5N1 influenza virus infection is afforded by intranasal inoculation with seasonal trivalent inactivated influenza vaccine. J Infect Dis 196:1313-1320.
11. Itoh Y, Ozaki H, Tsuchiya H, Okamoto K, Torii R, Sakoda Y, Kawaoka Y, Ogasawara K, Kida H. 2008. A vaccine prepared from a non-pathogenic H5N1 avian influenza virus strain confers protective immunity against highly pathogenic avian influenza virus infection in cynomolgus macaques. Vaccine 26:562-572.
12. Kida H, Brown LE, Webster RG. 1982. Biological activity of monoclonal antibodies to operationally defined antigenic regions on the hemagglutinin molecule of A/Seal/Massachusetts/1/80 (H7N7) influenza virus. Virology 122:38-47.
13. Mutsch M, Zhou W, Rhodes P, Bopp M, Chen RT, Linder T, Spyr C, Steffen R. 2004. Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. N Engl J Med 350:896-903.
14. Nicolson C, Major D, Wood JM, Robertson JS. 2005. Generation of influenza vaccine viruses on Vero cells by reverse genetics: An H5N1 candidate vaccine strain produced under a quality system. Vaccine 23:2943-2952.
15. Nishimura H, Itamura S, Iwasaki T, Kurata T, Tashiro M. 2000. Characterization of human influenza A (H5N1) virus infection in mice: Neuro-, pneumo- and adipotropic infection. J Gen Virol 81:2503-2510.
16. Rimmelzwaan GF, Kuiken T, van Amerongen G, Bestebroer TM, Fouchier RA, Osterhaus AD. 2001. Pathogenesis of influenza A (H5N1) virus infection in a primate model. J Virol 75:6687-6691.
17. Subbarao K, Klimov A, Katz J, Regnery H, Lim W, Hall H, Perdue M, Swayne D, Bender C, Huang J, Hemphill M, Rowe T, Shaw M, Xu X, Fukuda K, Cox N. 1998. Characterization of an avian influenza A (H5N1) virus isolated from a child with a fatal respiratory illness. Science (New York, NY) 279:393-396.
18. Tamura S, Tanimoto T, Kurata T. 2005. Mechanisms of broad cross-protection provided by influenza virus infection and their application to vaccines. Jpn J Infect Dis 58:195-207.
19. Tobita K. 1975. Permanent canine kidney (MDCK) cells for isolation and plaque assay of influenza B viruses. Med Microbiol Immunol 162:23-27.
20. Tobita K, Sugiura A, Enomote C, Furuyama M. 1975. Plaque assay and primary isolation of influenza A viruses in an established line of canine kidney cells (MDCK) in the presence of trypsin. Med Microbiol Immunol 162:9-14.